Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
Slika profila

Zdravko Anzulović

15272

Zdravko

Anzulović

mr. sc.

nije evidentirano
Naziv Akcije
Tarle, Marko ; Trnski, Davor ; Ružić, Boris ; Spajić, Boro ; Reljić, Ante ; Anzulović, Zdravko ; Katušić, Josip ; Kraus, Ognjen ; Ahel, Zaky ; Kraljić, Ivo. Neuroendocrine differentiation in subclinically detected prostate cancer and during a subsequent disease progression. // Anticancer Research / Delinassios, John (ur.). Atena: International Institute for Anticancer Research, 2001. str. 1660-1661-x
Tarle, Marko ; Kraljić, Ivo ; Ružić, Boris ; Anzulović, Zdravko ; Trnski, Davor ; Katušić, Josip ; Reljić, Ante ; Kovačić, Ksenija. Conversion of hormone sensitive prostate cancer to hormone resistant disease: A subclinical detection. // Anticancer Research, 18 (1998), 6c; 4958-4959-x
Tarle, Marko ; Kraus, Ognjen ; Kraljić, Ivo ; Trnski, Davor ; Anzulović, Zdravko ; Katušić, Josip ; Reljić, Ante ; Ružić, Boris Subclinical distinction of symptomatic BPH from prostate cancer in Finasteride treated patients. // Journal of tumor marker oncology. 1998. str. 32-33
Kraljić, Ivo ; Trnski, Davor ; Reljić, Ante ; Anzulović, Zdravko ; Tarle, Marko Introduction into the use of serum F/T%PSA value in distinguishing between BPH, latent and manifest prostatic adenocarcinoma // British Journal of Urology, 80 (1997), suppl. 2; 246-246-x
Ružić, Boris ; Reljić, Ante ; Trnski, Davor ; Kraus, Ognjen ; Anzulović, Zdravko ; Katušić, Josip ; Tarle, Marko Multivariate analysis of serum tumor markers in prostate cancer patients treated with triptorelin and maximal androgen blockade // Acta clinica Croatica, 36 (1997), 1; 41-48
Kraljić, Ivo ; Katušić, Josip ; Trnski, Davor ; Reljić, Ante ; Anzulović, Zdravko ; Ružić, Boris ; Tarle, Marko The use of free and total serum PSA values (F/T%PSA) in discriminating BPH from latent, manifest and "manifest-to-be" prostatic carcinoma // Journal of tumor marker oncology, 12 (1997), 4; 57-58-x
nije evidentirano
nije evidentirano